Pfizer has reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla, delaying generic competition for its blockbuster ATTR-CM drug Vyndamax until 2031. The move preserves ...
Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.
Pfizer has settled patent disputes with Cipla, Dexcel Pharma, and Hikma Pharmaceuticals over Vyndamax, extending U.S.
Pfizer Inc. announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in the US District ...
On April 28, Morgan Stanley reiterated an Equal Weight rating on Pfizer Inc. (NYSE:PFE). It also set a $28 price target on ...
US pharma giant Pfizer yesterday announced that it has entered into settlement agreements with generic drug manufacturers - ...
The FDA announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials ...
BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...
Good day, and welcome to Ionis' First Quarter 2026 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the over to Wade Walke, Senior Vice ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results